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Introduction
Delayed ischemic neurological deficit (DIND) and delayed cerebral 
infarction (DCI) are the most important postoperative risk factors for 
poor outcome after aneurysmal subarachnoid hemorrhage (SAH) [1]. 
Aneurysmal SAH is associated with a total mortality of estimately 50% 
including patients who die before admission to a hospital. In spite of 
new diagnostic tools, modern intensive care therapy and early aneurysm 
occlusion, the in-hospital mortality has remained at 25% [2] A large 
part of the surviving patients does not recover their pre-hemorrhage 
state [3]. Thus, SAH causes great personal harm and a great economical 
burden to health systems. 
Early brain damage in the first minutes after rupture of an 
aneurysm cannot be treated or reversed, as it usually occurs outside 
hospital walls. Treatment can begin when emergency physicians or 
paramedics have the first contact with the patient. At first, only general 
measures of treatment can be undertaken like analgesic therapy, 
application of oxygen or sometimes intubation and mechanical 
ventilation. Targeted therapy can be initiated not before the diagnosis 
of SAH has been established by a CT-scan. Later in the course of the 
disease, the patients are threatened by delayed ischemic events which 
arise several days after aneurysm rupture. Concerning these delayed 
perfusion deficits; however, there is the unique opportunity to start 
therapeutic measures in advance, before cerebral blood flow (CBF) 
declines below ischemic thresholds [4]. Various forms of treatment 
have been tested and used to enhance CBF and protect the brain from 
ischemic deficits. Among these, different calcium antagonists are the 
most prominent substances. Following the growing knowledge about 
pathophysiological mechanisms, a variety of further agents have been 
tested for their therapeutic efficacy. 
Pathophysiology
Aneurysmal SAH is characterized by 3 different forms of cerebral 
ischemia. First, global ischemia develops immediately after aneurysm 
rupture. The extravasation of blood into the subarachnoid space causes 
an increase of intracranial pressure (ICP) and subsequently a decrease 
of cerebral perfusion pressure (CPP). This stage of the disease cannot 
be therapeutically influenced because it occurs outside hospitals and 
before the diagnosis of SAH is established. An acute global vascular 
reaction also arises in the first seconds or minutes after aneurysm 
rupture, affects the entire cerebral vasculature at least for several hours 
even when CPP has recovered to normal [5].
 In the following days, a variety of local factors lead to endothelial 
dysfunction and changes in the contraction state of the vessels. They 
finally lead to structural changes of the vessel wall with intimal 
thickening and media proliferation [6]. Several days after SAH, delayed 
vasospasm develops in up to 70% of all patients who suffered from 
SAH. Until now, the exact pathogenesis is not clarified. Inflammatory 
processes are involved in this phenomenon and contribute to arterial 
narrowing [7]. The amount of subarachnoid blood is a good prognostic 
factor for the development of cerebral vasospasm and DIND indicating 
that hemoglobin in the subarachnoid space is the antigen that causes 
inflammatory reactions [8,9]. 
Nitric oxide (NO) induces the generation of cyclic guanosyl 
monophosphate (cGMP) which results in vasodilatation by several 
mechanisms [10,11]. Due to its high affinity, NO binds to hemoglobin, 
resulting in an NO-depletion. The number of perivascular neurons 
which carry relatively high amounts of NO and supply the large 
intracranial vessels, is decreased after SAH causing a further decrease 
of NO [12,13].
Free radicals are produced after SAH by a decay of leukocytes and 
by autooxidation of hemoglobin [7,14]. The degradation of membrane 
proteins and lipids are the consequence of the free radical activity 
resulting in a damage of endothelial cells, smooth muscle cells and 
perivascular neurons. Vasoactive substances are liberated, especially 
arachidonic acid metabolites. A direct inflow of calcium into vascular 
smooth muscle cells may be caused by a damage of the membrane 
integrity. 
Hemoglobin induces a radical-mediated damage of the cell 
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membrane and an activation of Phospholipase A2. Finally, a shift 
towards constrictive arachidonic acid metabolites occurs. The level 
of prostacyclin is reduced in the cerebral spinal fluid (CSF) of SAH-
patients who develop delayed vasospasm [15].
Endothelin-1 is the most powerful vasoconstrictive factor known 
to date. It has been found to be elevated in blood and CSF of patients 
who develop vasospasm after SAH. The elevation of Endothelin-1 levels 
correlate with the severity of vasospasm [16]. 
The extravasation of hemoglobin into the subarachnoid space is a 
toxic stimulus. The immune system reacts with a specific answer. Several 
hours after SAH, cellular adhesion molecules are found on the luminal 
surface of endothelial cells [17]. An inflammatory cascade develops, 
including the adhesion and extravasation of leukocytes. Different from 
other types of tissue, there is no clearance of the subarachnoid space 
by the lymphatic system. Therefore, leukocytes decay and vasoactive 
substances like Endothelin-1 and free radicals are set free. Cerebral 
vasospasm is likely not to be monofactorial. 
Today all these processes are thought to be factors of the 
development of arterial narrowing which is probably the basis of 
secondary ischemia evolving several days after aneurysmal SAH. 
However, arterial vasospasm seems not to be the only factor for the 
development of DCI after SAH. It has been shown that - although 
less frequently - DCI after SAH can occur without significant cerebral 
vasospasm [18]. On the other hand, the number of patients suffering 
from arterial vasospasm is much higher than the number of patient’s 
developing DCI [19]. Additional pathophysiological mechanisms 
have been proposed to induce secondary ischemia after SAH. Dreier 
et al. [20] and Pluta et al. [21] suggested a double-hit model of 
secondary ischemia in which mechanisms causing ion disturbances 
and hypermetabolism are superimposed on arterial narrowing and, 
in combination, cause DCI. Although the aetiology of DCI is not 
exactly known, all pathophysiological factors are likely to finally turn 
into a discrepancy between the supply and demand of oxygen in the 
brain. Following the growing knowledge about pathophysiological 
mechanisms, several attempts have been conducted to treat or prevent 
secondary ischemia after SAH and improve the outcome of SAH-
patients. 
Evidence for Drug Effectiveness in Clinical Trials
There is, at present, no specific agent of method that has proven 
clear efficacy for the treatment of early ischemia after SAH. The early 
management of SAH-patients includes intubation and mechanical 
ventilation if normal ventilation and oxygenation are at risk, 
ventriculostomy in case of occlusive hydrocephalus, medical treatment 
of elevated intracranial pressure (ICP), and early treatment of the 
aneurysm by surgical clipping or endovascular coiling, moderate hyper 
dynamic therapy to secure cerebral perfusion and the avoidance of 
medical complications. As secondary ischemic events after SAH occur 
with a delay of several days, there is the chance to start a specific 
neuroprotective treatment prior to ischemia. This is decisively different 
to embolic stroke which hits the patient at home or “in the field”, in 
most cases without prior warning signals [22]. A variety of substances 
have been tested in clinical trials. 
Corticosteroids
Inflammatory reactions are believed to be a decisive factor for the 
development of arterial narrowing after SAH [7,17]. Corticosteroids 
have an antiinflammatory effect, stabilize cell membranes and address 
the radical-induced cell damage and the effect of the calcium-influx into 
endothelial cells, smooth muscle cells, neurons and glial cells mediated 
by Phospholipase A2. The effectiveness of a high-dose therapy with 
corticosteroids after aneurysmal SAH, however, is not clarified to date. 
The mineralocorticoid fludrocortisone [23,24] and the glococotricoid 
hydrocortisone [25] have been tested in clinical studies. In a meta-
analysis, the therapy with corticosteroids did not show a distinct 
benefit for the patients [26]. Separately analyzed, the treatment with 
mineralocorticoids resulted in less ischemic complications. Serious 
side effects like gastrointestinal bleedings and electrolyte imbalance 
prevented a beneficial effect on outcome parameters in the treatment 
with hydrocortisone. In summary, the number of patients included 
in these three clinical trials is too small (256 patients) and the studies 
too inhomogenous to indicate a clear benefit of a corticosteroid 
treatment. Recently, a randomized, placebo-controlled clinical trial 
was published in which 95 patients with aneurysmal SAH received 
methylprednisolone in a daily dose of 16 mg/kg body weight for 3 days. 
The treatment resulted in an improvement of clinical outcome which 
nearly reached the level of significance [27]. 
Tirilazad 
Tirilazad mesylate is a 21-aminostroid with only very little 
mineralo- and glococorticoid activity. It acts as a radical scavenger 
and membrane protector [28]. The substance inhibits the free radical-
mediated damage of endothelial membranes and neurons. After 
promising results in experimental studies several clinical trials were 
conducted. In all of these studies, patietns were co-treated with the 
calcium antagonist nimodipine. A meta-analysis showed that the 
delayed arterial narrowing was reduced by treatment with tirilazad. 
However, this effect was not accompanied by a significant reduction of 
DCI and improvement of neurological outcome [29]. 
Statins
Hydroxymethylglutaryl coenzyme A reductase inhibitors, so-called 
“statins”, have a variety of properties which may potentially inhibit 
cerebral vasospasm. Among those are antiinflammatory activity and 
endothelial cell protection. Several clinical trials have been conducted. 
Early clinical studies revealed a lower incidence of cerebral vasospasm, 
vasospasm-related neurological deficits and mortality [30,31]. However, 
these trial were small and the end points varied strongly. More recent 
trials reported less promising results as they could not clearly reproduce 
the positive effects on vessel narrowing, DCI and neurological outcome 
[32,33]. The attempt to generate a Cochrane Review failed due to the 
poor quality of some trials and the inhomogenity of the available trials 
[34]. A closing statement about the usefulness of a statin treatment after 
SAH cannot be drawn. Further trials are on the way [35,36].
Endothelin-receptor antagonists
Three randomized clinical studies have been published in literature. 
One trial investigated a non-selective (ETA/ETB) Endothelin-receptor 
antagonist (TAK-044), two investigated the selective ETA-receptor 
antagonist Clazosentan [37-39]. The objective was to antagonize 
the strong vasoconstrictive activity exerted by ETA-receptors as 
Endothelin-1 concentrations are elevated in both blood and CSF of 
SAH-patients who develop delayed cerebral vasospasm.
A total of 867 patients was included in these trials. The treatment 
resulted in a distinct reduction of arterial narrowing (Odds Ratio 
(OR) 0.31). The incidence of DCI was less pronounced (OR 0.68) and 
there was only a marginal improvement of neurological outcome, 
determined as good (Glasgow outcome scale (GOS) 4 and 5) versus bad 
(GOS 1-3) outcome (OR 0.87). Mortality was even increased (OR 1.09) 
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[40]. The discrepancy between delayed cerebral vasospasm and DCI 
may be explainable by a hypotensive effect of ETA-receptor antagonists, 
which may prevent an improvement of cerebral perfusion in spite of 
attenuated arterial narrowing. The discrepancy between the reduced 
incidence of DCI and the failure to improve clinical outcome and even 
increased mortality may be explained by serious systemic side effects 
like pneumonia and pulmonary edema [40].
Calcium antagonists
In the 1980s and 1990s, a series of clinical trials was conducted 
to test the efficacy of pyrrolopyrimidine-type calcium antagonists. 
These substances were applied to inhibit cellular calcium influx in 
cerebrovascular smooth muscle cells via voltage-dependent L-type 
calcium channels which were suspected to be responsible for the 
occurrence of delayed cerebral vasospasm after SAH. It was registered 
rather quickly, that this kind of treatment did not prevent or dissolve 
arterial vasospasm. In a British clinical multicenter trial, however, a 
reduced incidence of DCI and improvement of clinical outcome by the 
oral treatment with nimodipine was observed [41]. Although this was 
the largest clinical trial, it was the only one that observed a significant 
benefit. A series of other trials with nimodipine and other calcium 
antagonists failed to reduce the incidence of DCI and improve outcome 
after SAH. A Cochrane Review edited in 2007 analyzed 7 prospective, 
randomized, placebo-controlled clinical trials with nimodipine and 
recommended its prophylactic administration in SAH-patients. 
However, the authors concluded that this recommendation was not 
“beyond any doubt”. If the above mentioned British multicenter trial 
was taken out of the statistical analysis, no more benefit over a placebo-
treatment could be calculated [42].
The prophylactic treatment with nimodipine has become a standard 
therapy in many centers. However, its standard use must be critically 
reviewed as there is a variety of conflicting issues regarding nimodipine. 
There is no evidence for the intravenous use, which was initially promoted 
by the manufacturer. The information about the oral uptake of the agent 
is scarce. In patients who are mechanically ventilated, oral nimodipine 
has to be administered via a stomach tube. Especially in the weaning 
phase after several days of mechanical ventilation, which parallels in 
many cases the period of maximum vasospasm, gastral reflux makes 
the uptake of orally administered substances incalculable. Nimodipine 
can cause hypotension and can open pulmonary arteriovenous shunts 
resulting in oxygenation problems. Finally, the meta-analyses about 
the use of calcium antagonists that are available today, refer to clinical 
trials that were conducted more than 25 years ago. The objective for 
a treatment with nimodipine and other calcium antagonists was the 
avoidance of delayed cerebral perfusion deficits. In the past 25 years, 
however, intensive care therapy has improved, many aneurysms are 
treated by endovascular coiling, and endovascular balloon dilatation 
and pharmacological vasospasmolysis are used to treat critical arterial 
narrowing of cerebral vessels and improve CBF [43]. The prerequisites 
have changed and it is doubtful whether a prophylactic oral treatment 
with nimodipine would still exert a beneficial effect under modern 
treatment standards [44]. 
Magnesium sulfate
Magnesium has been called “nature’s physiologic calcium blocker” 
as it is a physiological mineral and interferes with calcium in a variety 
of ways [45]. The bivalent magnesium cation can compete with calcium 
ions for receptor binding or passage through ion channels. It dilates 
blood vessels by competitive inhibition of voltage-dependent calcium 
channels in vascular smooth muscle cells [46], improves rheological 
functions by inhibition of platelet aggregation [47,48], and increases the 
deformability of red blood cells [49]. Under experimental conditions, 
it prevents cellular calcium influx and excitatory amino acid release 
in neurons by blockade of N-type and L-type calcium channels [50], 
prevents cellular calcium entry through NMDA-receptor channels 
[51], reduces calcium-induced mitochondrial dysfunction [52] and 
preserves cellular energy metabolism [53]. By these mechanisms, 
magnesium may inhibit or delay ischemic cell death during and after 
cerebral ischemic events. 
Low blood pressure is a risk factor for aggravation of ischemic 
damage in states of cerebral ischemia reducing collateral flow in the 
ischemic penumbra. Therefore, magnesium doses must be kept low 
enough to ensure stable blood pressure if it is administered for the 
purpose of neuroprotection. In an experimental study of temporary 
middle cerebral artery occlusion (MCAO) in rats, serum concentrations 
of 2.0-2.5 mmol/l showed the highest neuroprotective effect [54]. In 
higher doses, the cardiodepressive effect seems to limit the extent of 
neuroprotection.
The potential role for a treatment with magnesium was supported 
by the observation that hypomagnesemia is frequently found in SAH 
patients and correlates with the amount of blood in the subarachnoid 
space and with the patient’s neurological condition at the time of hospital 
admission. Hypomagnesemia arising during the course of treatment, 
in turn, correlates with the appearance of secondary neurological 
deficits and ischemic infarctions [55]. A series of clinical trials has 
been launched to assess the ability to reduce secondary neurological 
deficits after SAH. Several small observational studies and placebo-
controlled studies using different doses of intravenous magnesium 
sulfate produced promising results [56-61]. In a randomized, placebo-
controlled multicenter study conducted by van den Bergh et al., patients 
received a daily dose of 64 mmol MgSO4 for 14 days. The results were 
promising. Magnesium treatment reduced the risk of DCI by 34% and 
the risk for poor outcome by 23%. Including 283 patients, however, the 
study was still underpowered [62]. In a south-east Asian/Australian 
trial, 327 patients were randomized to receive placebo or a daily dose 
of 80 mmol/l MgSO4. The authors reported no significant benefit of 
magnesium-treatment regarding DCI and neurological outcome after 
6 months [63]. The largest clinical trial has been conducted by Mees et 
al. In this multicenter trial, 1,204 patients with aneurysmal SAH were 
enrolled and randomized to receive 64 mmol MgSO4 per day or placebo. 
The administration of MgSO4 did not improve clinical outcome at an 
end point 3 months after SAH [64].
These results also require a critical analysis. Except for a very 
small early clinical trial conducted by Luo et al. [56], who compared 
magnesium treatment to a true placebo group, all patients enrolled 
in these trials were co-treated with nimodipine. The authors of the 
latter studies conclude that intravenous magnesium fails to improve 
neurological outcome and mortality in spite of decreasing the incidence 
of DCI [65]. Among the trials, magnesium doses varied significantly. 
However, it is noticeable that all studies that found no benefit of 
magnesium-treatment used nimodipine as a “standard-treatment” 
which was administered to both the treatment-group and the “control-
group”. Schmid-Elsaesser et al. compared treatment with magnesium to 
treatment with nimodipine. Patients of the magnesium-group did not 
receive nimodipine. The authors did not register a significant difference 
between the two treatments arms [66]. In our own study, magnesium-
therapy was compared to a true placebo-group and resulted in a 
significant improvement of DCI and arterial spasm. Nimodipine was 
given to neither of both groups [67]. The combined administration 
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of magnesium and nimodipine is a combination therapy with two 
calcium antagonists. Therefore, it is not surprising that this treatment 
does not result in an additional effect as it is commonly known that 
the effect of a combination therapy is not necessarily the sum of its 
single components, in particular if both drugs have - in part or in total 
- the same mechanisms of action. The doses and co-medications vary 
too much to finally judge at this point whether magnesium may be an 
effective drug after aneurysmal SAH. 
In summary, the pharmacological attempts that have been 
conducted in the past were disappointing. The number of high-quality 
studies testing the efficacy of corticosteroids and statins is too small to 
supply evidence for their use in SAH-patients [25,34], radical scavengers 
and Endothelin-receptor antagonists have shown a positive effect 
regarding the treatment of delayed cerebral vasospasm but resulted in 
no improvement of DCI and neurological outcome [29,30]. Nimodipine 
has become a standard treatment on many centers although its use is not 
“beyond any doubt” as a Cochrane Review has stated [42]. Furthermore, 
the data on which the evidence for nimodipine-treatment bases, is 
more than 25 years old. In the meantime, treatment of aneurysms and 
vasospasm has been improved and a re-evaluation of nimodipine under 
new treatment standards must be called for [44]. Magnesium is cheap 
and safe to handle. However, recent trials have not found a significant 
protective effect if administered in addition to nimodipine [63,64]. 
If given without co-treatment with other calcium antagonists, it has 
shown a protective effect and might still be a promising substance in 
SAH-patients [66,67]. Due to these disappointing results, alternative 
methods may be interesting for the treatment of secondary ischemia 
after aneurysmal SAH.
Alternative Treatment Strategies and Future Prospects
Various attempts other than the systemic - oral or intravenous - 
administration of drugs have been conducted in order to treat delayed 
cerebral vasospasm and DCI. Some of these may have a high potential 
to become important forms of treatment. 
Subarachnoid washout
Subarachnoid blood or - more precisely - hemoglobin is the antigen 
that induces inflammatory reactions which ultimately lead to changes in 
the vessel walls and arterial narrowing [7]. The amount of subarachnoid 
blood determines the extent of delayed cerebral vasospasm [8]. In 
animal studies, the injection of blood into the subarachnoid space 
reproducibly leads to cerebral vasospasm with a delay of several days 
[68]. The removal of the subarachnoid blood clot may prevent or 
alleviate cerebral vasospasm if it is performed early enough [69,70]. 
In the practical setting, however, a complete or near-complete removal 
of the subarachnoid blood clot during aneurysm surgery seems too 
dangerous and is not reasonable. Several studies have been conducted 
to dissolve the blood clot by fibrinolytic agents. First clinical experience 
was gathered in the 1980s. Tsementzis et al. reported that this method 
is safe in SAH-patients [71]. In a small number of patients, Hamada 
et al. administered urokinase via an intrathecal catheter and found a 
complete removal of the subarachnoid blood clot as visible in CT-scans 
within 24 hours. None of these patients developed DCI [72]. Yamamoto 
et al. administered tissue plasminogen activator (tPA) continuously or 
intermittently via a cisternal catheter which was positioned during 
surgical clipping of the aneurysm and compared two treatment-groups 
(continuous or intermittent administration) to a control group. The 
authors found no relevant risks of intrathecal fibrinolytic therapy, a 
reduction of ischemic events and an improvement of neurological 
outcome in the treatment-groups favoring the intermittent 
administration [73]. The patient collectives were too small to draw firm 
conclusions. However, the absence of side effects and the positive results 
with regard to secondary ischemic events make intrathecal fibrinolytic 
therapy a promising treatment. 
Continuous head motion and rotational therapy for 
subarachnoid lavage
The objective of this manipulation is to accelerate the washout 
of blood by a continuous motion of the head. This form of treatment 
was first described by Suzuki et al. in 1990 and later picked up by 
Kawamoto et al. [74,75]. Kawamoto et al. reported about a marked 
reduction of delayed vasospasm, DIND and DCI and an improvement 
of neurological outcome by continuous head motion combined with 
cisternal irrigation. Eicker et al. combined continuous low-frequency 
head motion with fibrinolytic therapy in 40 patients and reported a 
significant decrease of DCI [76]. 
Intrathecal delivery of vasodilators
To date, the intrathecal administration of vasodilators, calcium 
antagonists (Table 1) and sodium nitroprussid (SNP) (Table 2) has 
been performed in particular cases with cerebral vasospasm which is 
Author Agent and application Patient collective Results Methodical side effects
Pharmacological 
side effects Remark
Shibuya et al., 
1994 [84]
Nicardipine via cisternal catheter 
(3 x 2 mg daily from day 10-17)
Patients with high risk of 
vasospasm (Fisher grade 3) 
(50 treatment, 91 control)
50% reduction of DIND, 
reduction of angiographic 
vasospasm
2 Meningitis Headache Not randomized
Suzuki et al., 
2001 [85]
Nicardipine via cisternal catheter 
(2 x 4 mg fromday 3-14)
177 consecutive SAH 
patients
Low rate of angiographic 
vasospasm and DIND 6% meningitis None
No controlled 
study
Fujiwara et al., 
2001 [86]
Nicardipin via cisternal catheter 
(continuous administration of 8 
mg daily for 14 days)
5 patients with high risk of 
vasospasm 
No angiographic vasospasm, 
reversible DIND in 1 patient 1 meningitis None
No controlled 
study
Etisham et al., 
2008 [87]
Nicardipin via EVD (2 x 4 mg 
daily over several days) 6 patients with vasospasm
Marked reduction of flow 
velocity in TCD after nicardipine 
administration in 5 patients
None None No controlled study
Goodson et al, 
2008 [88]
Nicardipin via EVD (2 x 4 mg 
daily over 5-17 days)
8 patients with refractory 
vasospasm
Good outcome in 7 patients, 
death in 1 patients None
headache in 1 
patient
No controlled 
study
Hänggi et al. 
2008 [89]
Nimodipine (0.4 mg bolus via 
EVD followed by continuous 
infusion of 0.4 mg/h via lumbar 
drainage
8 patients with refractory 
vasospasm
Immediated improvement 
in 3 patients, improved 
perfusion (Perfusion-CT) in 
70%. Improved angiographic 
vasospasm in 7 patients.
1 meningitis None No controlled study
Table 1: Clinical studies on the treatment of cerebral vasospasm with calcium antagonists via cisternal or ventricular catheters (DIND=delayed ischemic neurological deficit, 
TCD=transcranial Doppler sonography).
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refractory to medical and endovascular treatment or prophylactically in 
patients who were considered to have a particularly high risk to develop 
delayed cerebral vasospasm and DIND. Apart from this, nicardipine, 
a calcium antagonist was prophylactically attached to cerebral vessels 
during surgical clipping of aneurysms in the shape of “pellets” which 
dissolve slowly and continuously release the agent (Table 3). The results 
were reproducibly positive as intrathecal therapy tended to prevent 
vasospasm and even reverse vasospasm which was refractory to medical 
treatment. However, there is no randomized, placebo-controlled trial 
which supplies good evidence for intrathecal treatment. 
Again, magnesium may be a promising substance for intrathecal 
administration. It is a physiological component of CSF and a moderate 
increase of its CSF concentration is unlikely to produce serious side 
effects. Furthermore, the CSF concentration can easily be followed by 
laboratory analyses. However, experimental studies suggest that CSF 
concentrations of 2-4 mmol/l are necessary to dilate spastic vessels 
[77,78]. These concentrations cannot be produced by an intravenous 
administration of magnesium sulfate since the systemic side effects 
could be hazardous. Mori et al administered magnesium sulfate via 
a cisternal catheter in patients with cerebral vasospasm refractory to 
other forms of therapy and found a reduction of the extent of arterial 
narrowing [79], measured by transcranial Doppler sonography.
Carbon dioxide
Cerebral autoregulation upon changes of arterial blood pressure 
is deranged after aneurysmal SAH. The cerebrovascular reactivity on 
changes of arterial CO2 concentrations, however, may be altered but is 
still preserved [80,81]. It is well known that hyperventilation enhances 
cerebral perfusion deficits after SAH and induces ischemia [82].
A series of studies has been published investigating the reactivity 
of CBF on changes of arterial CO2 concentrations and their prognostic 
relevance for the development of DCI after SAH. Recently, Carrera et al. 
found that decreased cerebrovascular reactivity on changes of arterial 
CO2 is associated with a higher risk to develop cerebral ischemia [83]. 
Until now, this basic physiological regulation mechanism has not been 
Author Agent and application Patient collective Results Methodical side effects
Pharmacological 
side effects Remark
Thomas et al., 
1999 [90]
SNP via EVD or cisternal catheter 
Group 1: 7-88 mg SNP until 
improvement of spasm or 
occurrence of side effect
Group 2: 4-8 mg SNP every 6 
hours for 5-17 days
Group 1: 15 patients 
with refractory 
vasospasm
Group 2: 10 patients 
prophylactically (Fisher 
grade 3, Hunt/Hess 
grade 3-5) 
Group 1: improvement of 
angiographic vasospasm in 8 
patients
Group 2: no signs of vasospasm 
None
Group 1: 
hypotension in 3 
cases, nausea in 2 
cases
Group 2: None
No controlled study, 
not randomised
Thomas et al., 
2002 [91]
SNP+Thiosulfat via EVD (4 mg/ml 
und 10 mg/ml) 
“acute protocol”: 10 ml in 10 single 
doses every 5 minutes
“prophylactic protocol”: 2 ml over 
60 minutes for 11-14 days
“acute protocol”: 10 
patients with DIND or 
elevated flow velocities 
in TCD
“prophylactic protocol”: 
6 patients 
Improvement of DIND and flow 
velocities in TCD in 9/10 cases None None No controlled study
Raabe et al., 
2002 [92]
SNP via EVD or cisternal catheter
single bolus 10-40 mg (11 
patients) 
continuous infusion 2-8 mg for 
7-14 days
13 patients with 
refractory vasospasm
Tissue oxygenation improved in 6 
patients with vasospasm None
Hypotension in 5 
cases, nausea in 
3 cases, cardiac 
arrhythmias in 1 
case
No controlled study, 
not randomized
Pathak et al., 
2003 [93] 
SNP “high-dose” (5 mg every 4-12 
hours via EVD)
SNP “low-dose” (4 mg every 6 
hours via cisternal catheter
“high-dose”: 5 patients 
with DIND
“low-dose”: 3 patients 
with SAH Fisher grade 3
reduction of flow velocity in TCD
No spasm in 2, moderate spasm 
in 1 prophylactically treated 
patients
None
Distinct 
hypotension after 
administration of 
SNP
Not randomised
Kumar et al., 
2003 [94]
SNP via EVD
Repeated administration of 4 mg 
bolus
10 patients with SAH
improvement or complete 
recovery of vasospasm in all 
patients
None
Nausea in higher 
doses, hypotension 
in 2 cases
No controlled study, 
not randomized
Table 2: Clinical trials assessing the effects of intrathecal administration of sodium nitroprussid in patients with refractory vasospasm and patients with high risk to develop 
vasospasm and DCI (SNP=sodium nitroprussid, EVD=external ventricular catheter, TCD=transcranial Doppler sonography).
Author Agent and Application Patient Collective Results Methodical Side Effects
Pharmacological 
Side Effects Remark
Dalbasti et al., 2001 
[95]
Papaverin pellets 
intraoperative positioning 
of pellets
117 patients with high risk of 
vasospasm (73 treatment, 44 
control)
marked reduction of 
vasospsm, significant 
improvement of outcome
None None No randomisation
Kasuya et al., 2005 
[96]
Nicardipin pellets, 
intraoperative positioning 
of pellets
125 patients with high risk of 
vasospasm (97 treatment, 28 
control)
mignificant reduction of 
DIND None None No randomisation
Krischek et al., 2007 
[97] 
Nicardipine pellets 
intraoperative positioning 
of pellets
100 patients with high risk of 
vasospasm (Fisher grade 2 
und 3)
7 patients with DIND, 5 
patients with DCI.
No spasms in vicinity to 
pellets
None None No randomisation
Barth et al., 2007 [98]
Nicardipine pellets, 
intraoperative positioning 
of pellets
32 patients (16 treatment, 16 
control)
reduction of angiographic 
vasospasm and DIND, 
improvement of neurological 
outcome
None None Randomized study
Table 3: Clinical studies assessing the efficacy of intraoperatively positioned drug-releasing “pellets” containing vasodilating agents (DIND=delayed ischemic neurological 
deficit).
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17. Gallia GL, Tamargo RJ (2006) Leukocyte-endothelial cell interactions in chronic 
vasospasm after subarachnoid hemorrhage. Neurol Res 28: 750-758.
18. Brown RJ, Kumar A, Dhar R, Sampson TR, Diringer MN (2013) The relationship 
between delayed infarcts and angiographic vasospasm after aneurysmal 
subarachnoid hemorrhage. Neurosurgery 72: 702-707.
19. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, et al. 
(2009) Defining vasospasm after subarachnoid hemorrhage: what is the most 
clinically relevant definition? Stroke 40: 1963-1968.
20. Dreier JP, Ebert N, Priller J, Megow D, Lindauer U, et al. (2000) Products of 
hemolysis in the subarachnoid space inducing spreading ischemia in the cortex 
and focal necrosis in rats: a model for delayed ischemic neurological deficits 
after subarachnoid hemorrhage? J Neurosurg 93: 658-666.
21. Pluta RM (2005) Delayed cerebral vasospasm and nitric oxide: review, new 
hypothesis, and proposed treatment. Pharmacol Ther 105: 23-56.
22. Muir KW, Lees KR, Ford I, Davis S; Intravenous Magnesium Efficacy in Stroke 
(IMAGES) Study Investigators (2004) Magnesium for acute stroke (Intravenous 
Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 363: 
439-445.
23. Hasan D, Lindsay KW, Wijdicks EF, Murray GD, Brouwers PJ, et al. (1989) 
Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. 
Stroke 20: 1156-1161.
24. Mori T, Katayama Y, Kawamata T, Hirayama T (1999) Improved efficiency of 
hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients 
with aneurysmal subarachnoid hemorrhage. J Neurosurg 91: 947-952.
25. Hashi K, Takakura K, Sano K, Ohta T, Saito I, et al. (1988) [Intravenous 
hydrocortisone in large doses in the treatment of delayed ischemic neurological 
deficits following subarachnoid hemorrhage--results of a multi-center controlled 
double-blind clinical study]. No To Shinkei 40: 373-382.
26. Feigin VL, Anderson N, Rinkel GJ, Algra A, van Gijn J, et al. (2005) 
Corticosteroids for aneurysmal subarachnoid haemorrhage and primary 
intracerebral haemorrhage. Cochrane Database Syst Rev : CD004583.
27. Gomis P, Graftieaux JP, Sercombe R, Hettler D, Scherpereel B, et al. 
(2010) Randomized, double-blind, placebo-controlled, pilot trial of high-dose 
methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg 
112: 681-688.
28. Braughler JM, Pregenzer JF (1989) The 21-aminosteroid inhibitors of lipid 
peroxidation: reactions with lipid peroxyl and phenoxy radicals. Free Radic Biol 
Med 7: 125-130.
29. Zhang S, Wang L, Liu M, Wu B (2010) Tirilazad for aneurysmal subarachnoid 
haemorrhage. Cochrane Database Syst Rev : CD006778.
30. Lynch JR, Wang H, McGirt MJ, Floyd J, Friedman AH, et al. (2005) Simvastatin 
reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a 
pilot randomized clinical trial. Stroke 36: 2024-2026.
31. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ (2005) Effects 
of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and 
delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase 
II randomized placebo-controlled trial. Stroke 36: 1627-1632.
32. Vergouwen MD, Meijers JC, Geskus RB, Coert BA, Horn J et al. (2009) Biologic 
effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a 
double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab 
29: 1444-1453. 
33. Chou SH, Smith EE, Badjatia N, Nogueira RG, Sims JR 2nd, et al. (2008) 
A randomized, double-blind, placebo-controlled pilot study of simvastatin in 
aneurysmal subarachnoid hemorrhage. Stroke 39: 2891-2893.
34. Liu Z, Liu L, Zhang Z, Chen Z, Zhao B (2013) Cholesterol-reducing agents 
for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 4: 
CD008184.
35. Wong GK, Liang M, Tan H, Lee MW, Po YC, et al. (2013) High-dose simvastatin 
for aneurysmal subarachnoid hemorrhage: a multicenter, randomized, 
controlled, double-blind clinical trial protocol. Neurosurgery 72: 840-844.
36. Garg K, Sinha S, Kale SS, Chandra PS, Suri A, et al. (2013) Role of simvastatin 
in prevention of vasospasm and improving functional outcome after aneurysmal 
sub-arachnoid hemorrhage: a prospective, randomized, double-blind, placebo-
controlled pilot trial. Br J Neurosurg 27: 181-186.
37. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, et al. (2008) 
used therapeutically, although hypercapnia by inhalation of CO2 or by 
reduction of the respiratory volume in mechanically ventilated patients 
may rapidly cause an enhancement of CBF. There may be a therapeutic 
potential to treat patients in a state of critical brain perfusion. A clinical 
trial investigating this phenomenon is currently on the way (www.
clinicaltrials.gov, ID: NCT01799525).
A variety of interesting clinical trials has investigated alternative 
methods to treat delayed cerebral vasospasm after aneurysmal SAH. 
The numbers are too small and the investigations not structured 
enough to implement them into standard therapy yet. However, there 
may be a high therapeutic potential in these methods and possibly their 
combinations to treat patients in this critical condition.
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